Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing
years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a …

Different tau biomarkers become abnormal at different stages of Alzheimer's disease, with
CSF phospho-tau typically becoming elevated at subthreshold levels of tau-PET binding. To …

Introduction Due to the segmented functions and complexity of the human brain, the
characterization of molecular profiles within specific areas such as brain structures and …

The mechanisms by which the apolipoprotein E ε4 (APOE ε4) allele influences the
pathophysiological progression of Alzheimer's disease (AD) are poorly understood. Here we …

Background: Liver steatosis and fibrosis are emerging as risk factors for multiple
extrahepatic health conditions; however, their relationship with Alzheimer's disease …

Introduction Alzheimer's (AD) and Parkinson's disease (PD) are neurodegenerative
conditions characterized by incremental deposition of β-amyloid (Aβ) and α-synuclein in AD …

Introduction We evaluated for two novel automated biomarker assays how cerebrospinal
fluid (CSF) amyloid beta (Aβ) 1–42‐ratios improved the concordance with amyloid positron …